Target intelligence / Profile preview

Pathogens, autoantigens, and autoantibodies

Molecular classification
Other
01

Overview

Pathogens, autoantigens, and autoantibodies represent the complex tripartite interplay involved in the initiation and progression of autoimmune diseases (Smatti et al., 2019, Frontiers in Microbiology). Pathogens, such as viruses and bacteria, are frequently identified as environmental triggers that can initiate autoimmunity through mechanisms like molecular mimicry, where microbial antigens share structural similarities with host proteins (Cusick et al., 2012, Clinical Reviews in Allergy & Immunology). Autoantigens are the specific endogenous molecules, such as double-stranded DNA or myelin basic protein, that become the targets of a misdirected immune response. Autoantibodies are the immunoglobulins produced by B cells that bind to these autoantigens, serving as both diagnostic biomarkers and active mediators of tissue damage and inflammation (Ludwig et al., 2017, Frontiers in Immunology). This collective concept is fundamental to understanding the etiology of conditions like Systemic Lupus Erythematosus and Multiple Sclerosis, but it does not constitute a single druggable target. Instead, therapeutic strategies focus on specific components within this axis, such as B-cell depletion, cytokine inhibition, or the management of underlying infections.

Other names
Infectious triggers of autoimmunityMolecular mimicry componentsAutoimmune triadPathogen-induced autoimmunity
02

Mechanism of action

Not applicable as this represents a broad category of biological entities rather than a single therapeutic target.

03

Biological functions

Immune responsePathogenesisMolecular mimicryAntigen presentationB-cell activation
04

Disease associations

Autoimmune diseaseInfectionInflammationSystemic lupus erythematosusRheumatoid arthritis
05

Safety considerations

Systemic immunosuppressionRisk of opportunistic infectionsReactivation of latent pathogensDifficulty in achieving antigen-specific tolerance
06

Biomarkers

Antinuclear antibodies (ANA)Rheumatoid factor (RF)Anti-citrullinated protein antibodies (ACPA)Pathogen-specific serologyHLA-DRB1 alleles

Beyond the preview

Go deeper on Pathogens, autoantigens, and autoantibodies.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogens, autoantigens, and autoantibodies.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call